Upcoming Conferences and Events in October
CAMBRIDGE, Mass., September 30, 2026 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming October 2026 conferences and events, and will be available for one-on-one meetings.
Details are as follows:
H.C. Wainwright Biotech On Tap 2026
Date: September 30-October 2
Location: Munich, Germany
Participant: Neil Warma, Chief Executive Officer, ProMIS Neurosciences
Lausanne XIII 13th Annual Workshop
Date: October 6-8, 2026
Location: Lausanne, Switzerland
Participant: Neil Warma, Chief Executive Officer, ProMIS Neurosciences
The Lausanne Workshop is an annual global convening dedicated to stopping Alzheimer's disease. Since 2014, it has united leaders from industry, government, academia, and civil society to drive candid, solutions-focused dialogue.
Chardan’s 10th Annual Healthcare Conference
Date: Tuesday, October 20, 2 pm. ET
Location: New York, NY
Panel title: Targeting Neurodegenerative & Neuromuscular Disease: ALS, DMD, Alzheimer's & Parkinson's
Participants: Larry Altstiel, Chief Medical Officer, ProMIS Neurosciences; Moderated by Keay Nakae, Director of Research and a Senior Research Analyst at Chardan Capital Markets
Greater Boston Walk to End Alzheimer’s
Date: Sunday, October 25
Location: Cambridge, MA
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS’ lead asset in Phase 1b development, PMN310, is a humanized IgG1 monoclonal antibody designed to selectively target only the toxic oligomers of amyloid-beta (AβOs), believed to be among the earliest and most damaging drivers of Alzheimer’s disease, while avoiding binding to amyloid plaques and vascular deposits. ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
Investor Relations Contact:
Carie Pierce, VP, Investor Relations & External Affairs
IR@promisneurosciences.com
Released September 30, 2026